Thromb Haemost 1977; 38(02): 0438-0446
DOI: 10.1055/s-0038-1651479
Original Article
Schattauer GmbH

The Activation of Plasma Factor XIII with the Snake Venom Enzymes Ancrod and Batroxobin Marajoensis

M Walter
1   Coagulation and Fibrinolysis Laboratories, Kantonsspital, Basle, Switzerland
,
D Nyman
1   Coagulation and Fibrinolysis Laboratories, Kantonsspital, Basle, Switzerland
,
V Krajnc
1   Coagulation and Fibrinolysis Laboratories, Kantonsspital, Basle, Switzerland
,
F Duckert
1   Coagulation and Fibrinolysis Laboratories, Kantonsspital, Basle, Switzerland
› Author Affiliations
Further Information

Publication History

Received 06 December 1976

Accepted 30 March 1977

Publication Date:
04 July 2018 (online)

Summary

The snake venom enzymes Ancrod and Batroxobin marajoensis are able to activate human plasma factor XIII as shown by the formation of the γ-dimers. The concentration of γ-dimers increases with the concentration of the activating enzymes. Factor XIII activated by Ancrod or Batroxobin marajoensis is, however, unable to catalyse the incorporation of the amine dansylcadaverine into casein. The partially activated factor XIII is therefore not demonstrable by means of the artificial test system. This factor XIII loses little activity and remains activable by thrombin.

 
  • References

  • 1 Barlow G. H, Holleman W. H, Lorand L. 1970; The action of Arvin on fibrin stabilizing factor (factor XIII). Research Communications in Chemical Pathology and Pharmacology 1: 39.
  • 2 Bohn H, Schwick G. H. 1971; Isolierung und Charakterisierung eines fibrinstabilisierenden Faktors aus menschlichen Plazenten. Arzneimittelforschung 21: 1432.
  • 3 Clauss A. 1957; Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta haematologica 17: 237.
  • 4 Edgar W, Prentice C. R. M. 1973; The proteolytic action of Ancrod on human fibrinogen and its polypeptide chains. Thrombosis Research 2: 85.
  • 5 Gaffney P. J, Brasher M. 1974; Mode of action of Ancrod as a defibrinating agent. Nature 251: 53.
  • 6 Koller F, Loeliger E. A, Duckert F. 1951; Experiments on a new clotting factor (factor VII). Acta haematologica 6: 1.
  • 7 Kopéc M, Latallo Z. S, Stahl M, Wegrzynowicz Z. 1969; The effect of proteolytic enzymes on fibrin stabilizing factor. Biochimica et biophysica Acta 181: 437.
  • 8 Lorand L, Downey J, Gotoh T, Jacobsen A, ToKura S. 1968; The transpeptidase system which crosslinks fibrin by γ-glutamyl-ε-lysine bonds. Biochemical and biophysical Research Communications 31: 222.
  • 9 Lorand L, Urayama T, de Kiewiet J. W. C, Nossel H. L. 1969; Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. Journal of clinical Investigation 48: 1054.
  • 10 Matacic S, Loewy A. G. 1968; The identification of isopeptide crosslinks in insoluble fibrin. Biochemical and biophysical Research Communications 30: 356.
  • 11 McDonagh R. P, McDonagh J, Duckert F. 1971; The influence of fibrin crosslinking on the kinetics of urokinase induced clot lysis. British Journal of Haematology 21: 323.
  • 12 McDonagh J, McDonagh R. P. 1975; Alternative pathways for the activation of factor XIII. British Journal of Heamatology 30: 465.
  • 13 McKee P. A, Mattock P, Hill R. L. 1970; Subunit structure of human fibrinogen, soluble fibrin and crosslinked insoluble fibrin. Proceedings of the National Academy of Sciences U.S. A 66: 738.
  • 14 Pisano J. J, Finlayson J. S, Peyton M. P. 1968; Cross-link in fibrin polymerized by factor XIII: ε (γ-glutamyl) lysine. Science 160: 892.
  • 15 Schwartz M. L, Pizzo S. V, Hill R. L, McKee P. A. 1973; Human factor XIII from plasma and platelets. Journal of biological Biochemistry 248: 1395.
  • 16 Stocker H. 1975 Personal communication.